Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Morris on rPFS as an Endpoint in Clinical Trials

May 22nd 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Dr. Sandler on Radiation Therapy for Prostate Cancer

May 21st 2013

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

Dr. Crawford on Sequences and Combinations in CRPC

May 20th 2013

E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.

Beyond Provenge: The Next Steps With Immunotherapy in Prostate Cancer

May 17th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.

Dr. Karsh Discusses Treatment Sequencing in mCRPC

May 17th 2013

Lawrence Karsh, MD, from The Urology Center of Colorado, discusses strategies for sequencing treatments for men with metastatic castration-resistant prostate cancer.

Dr. Morris Discusses PET Imaging in Prostate Cancer

May 16th 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.

Radium-223 Approved For Advanced Prostate Cancer

May 15th 2013

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

Dr. Scher on Key Findings From the COU-AA-302 Trial

May 13th 2013

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.

Bone-Targeted Therapies Evolve in Prostate Cancer

May 13th 2013

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Dr. Mark Scholz on Advances in Prostate Cancer Imaging

May 10th 2013

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.

Integrating New Therapies Into the Prostate Cancer Continuum

May 9th 2013

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

AUA Offers Evidence-Based Guide For Sequencing CRPC Therapies

May 6th 2013

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

AUA Abstract Roundup

May 6th 2013

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

Use of Expectant Management Lags in Prostate Cancer

May 5th 2013

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

Dr. Petrylak Describes the Investigation of PROSTVAC

May 3rd 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Dr. Sandler on Orteronel in High-Risk Prostate Cancer

May 1st 2013

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

Worldwide Effort Yields Major Advances in Identifying Genetic Risks for Breast, Prostate, and Ovarian Cancer

April 30th 2013

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Use of Sipuleucel-T Refined

April 30th 2013

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

Dr. Crawford on the Prostate Cancer Treatment Landscape

April 25th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the rapidly changing treatment landscape for men with advanced prostate cancer.

Dr. Dreicer on Prostate Cancer Drug Development Challenges

April 23rd 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses challenges facing the development of new lyase inhibitors and androgen receptor antagonists as treatments for men with prostate cancer.